RT Journal Article
SR Electronic
T1 Safety and efficacy of antiviral therapy alone or in combination in COVID-19 - a randomized controlled trial (SEV COVID Trial)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.06.21258091
DO 10.1101/2021.06.06.21258091
A1 ,
A1 Singh, Budha O
A1 Moirangthem, Bikram
A1 Panda, Prasan Kumar
A1 Bahurupi, Yogesh Arvind
A1 Saha, Sarama
A1 Saini, Girraj
A1 Dhar, Minakshi
A1 Bairwa, Mukesh
A1 Pai, Venkatesh Srinivasa
A1 Agarwal, Ankit
A1 Sindhwani, Girish
A1 Handu, Shailendra
A1 Ravikant,
YR 2021
UL http://medrxiv.org/content/early/2021/06/08/2021.06.06.21258091.abstract
AB Background Definitive antiviral treatment is not available for COVID-19 infection except remdesivir that even with many doubts. Various combination antivirals have been tried.Methods A single-center, open-label, parallel-arm, stratified randomized controlled trial evaluated the therapeutic potential of hydroxychloroquine and lopinavir-ritonavir in combination with ribavirin in COVID-19. Enrolled patients in severe category were randomized into three groups: A: standard treatment, B: hydroxychloroquine+ribavirin+standard treatment, or C: lopinavir+ritonavir+ribavirin+standard treatment; while non-severe category into two groups: A: standard treatment or B: hydroxychloroquine+ribavirin. Combination antivirals was given for 10 days and followed for 28 days. The primary endpoints were safety, symptomatic and laboratory recovery of organ dysfunctions, and time to SARS-CoV-2 RT-PCR negative report.Results Total 111 patients randomized: 24, 23, and 24 in severe category A, B, and C respectively, and 20 in each non-severe group. Two patients receiving ribavirin experienced drug induced liver injury and another developed QT prolongation after hydroxychloroquine. In the severe category, 47.6%, 55%, and 30.09% in A, B, and C groups respectively showed symptomatic recovery compared to 93.3% and 86.7% in A and B groups respectively in the non-severe category at 72hrs (P>0.05).Conclusions The results failed to show statistical superiority of the antiviral combination therapies to that of the standard therapy in both the severe and non-severe categories in symptomatic adult patients of COVID-19. However, results do indicate the benefit of non-standard interventional combination therapy in severe disease. Furthermore, the dose of ribavirin needs to be reconsidered in the Indian population.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialCTRI/2020/06/025575Funding StatementNon-fundedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This trial was approved by the Institutional Ethics Committee of AIIMS, Rishikesh on 30/05/2020 with reference no. 218/IEC/IM/NF/2020. Written informed consent was obtained from all participants.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIt will be provided with permission from the Corresponding author.